Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“ASCO26 developmental therapeutics presentation- ASP2998- Trop2 targeting immunostimulatory ADC (antibody drug conjugate) with dual payload (Topo1 inhibitor plus STING agonist)- enrolling patients with multiple solid cancers- exciting phase 1 clinical trial in progress globally including Adventhealth Cancer Institute, AdventHealth Central Florida Orlando, Florida – thanks to Astellas Pharma – and our great team.”
More posts featuring Guru Sonpavde.